BioSpace

Study reveals new role for tau, a top target for Alzheimer’s drug development

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

Utah reports 48 cyclospora cases, all but 5 could be tied to travel

Novo Nordisk shares slide after guidance disappoints investors

Why Pfizer Just Hiked Its Guidance By $500 Million

Micron, Bristol Myers, Palantir, Circle Internet, SpaceX, and More Stocks That Explain Today’s Market

Replimune’s twice-rejected melanoma drug prevails in FDA adcomm

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

The FDA has granted approval to Otsuka for Simtriyo, marking the introduction of the first triple reuptake inhibitor for the treatment of ADHD.

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

FDA staff flags data concerns about Capricor's therapy; shares plunge

Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Why Arrowhead Shot Sky-High, While Ionis Toppled

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA releases 14 drug rejection letters after 3-month pause

FDA resumes releasing drug rejection letters after 3-month pause

This Week in Science: Knee Pain Relief, a Superconductor Record, And More!

A new minimally invasive procedure using tiny beads may significantly reduce knee osteoarthritis pain and delay the need for replacement surgery.

Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback

Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.

FDA’s top gene therapy regulator is leaving his role

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

The FDA has launched a new initiative to accelerate the review process for new pharmaceutical manufacturing facilities.

Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope

An experimental drug targeting pancreatic cancer is showing promising survival gains in clinical trials.

Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers